2015
Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
Gehrie E, Tormey C. Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal. Archives Of Pathology & Laboratory Medicine 2015, 139: 687-92. PMID: 25927153, DOI: 10.5858/arpa.2013-0677-rs.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsManagement of NOACOral direct thrombin inhibitorDirect factor Xa inhibitorVitamin K antagonistsDirect thrombin inhibitorFactor Xa inhibitorsCertain clinical circumstancesOral anticoagulationWarfarin effectivenessK antagonistsOral anticoagulantsClinical efficacySafety profileEmergent reversalClinical circumstancesXa inhibitorsUS FoodDrug AdministrationThrombin inhibitorsNew drugsDrugsEfficacyInhibitorsLaboratory assays
2013
Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients
Winkler AM, Tormey CA. Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal Of Clinical Pathology 2013, 140: 610-622. PMID: 24124139, DOI: 10.1309/ajcp9vjs6kuknchw.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorAvailable direct thrombin inhibitorThrombin inhibitorsDegree of anticoagulationLife-threatening bleedsExperimental animal modelsSupportive careBleeding patientsCase reportClinical trialsFactor concentratesRoutine coagulationAnticoagulant effectPharmacologic propertiesAnimal modelsThrombin timeTransfusion productsPathology consultationAnticoagulationDrug concentrationsLaboratory assessmentNewer assaysDrug removalBleedingPrimary author